Sotera Health is no longer a sponsor leftover priced mainly for legal fear. The May chief-executive handoff and the completed private-equity exit recast the equity as a test of whether a high-margin sterilization franchise, now sitting at the top of its long-stated leverage band, can be valued as a durable compounder rather than a contingent claim. Net leverage reached three times at mid-year, which is the ceiling of the band management has advertised for years. The operating print is the evidence that the franchise still works. Remaining ethylene oxide cases in Georgia and California are the discount that still sits on the multiple.
The June quarter showed the company still prices and fills chambers through a hard year-ago comparison. Sterigenics carried most of the growth on value-based pricing and a large customer shifting work onto the network. Nordion's cobalt harvest timing flattered the print and is not a clean run-rate. Nelson Labs snapped back after a soft start, which is the first useful read on whether the lab franchise is a growth partner or a drag. Cash from operations of $88 million arrived after the last reserved Illinois settlement cleared the balance sheet.
Guidance moved higher after the first half, but only at the edges. Shares near $19 already sit close to the top of the yearly range on a mid-teens forward earnings multiple. The open question is whether Georgia's remaining personal-injury docket and the Vernon trials scheduled for early next year stay contained enough for that multiple to hold, or whether another cash settlement cycle pulls leverage back out of the target range.